Roche buys German cancer diagnostics firm

Roche has signed an agreement to acquire mtm laboratories, a privately-held German in vitro diagnostics company which specialises in  early detection of cervical cancer. Under the terms of the deal, the Swiss major will pay shareholders in the Heidelberg-based group an upfront payment of around 130 million euros, plus an extra 60 million euros “upon

Continue Reading

GSK Expands Vaccine Presence in China

GlaxoSmithKline (GSK) has entered into an agreement to purchase Shenzhen Neptunus’ stake in a previously formed joint venture between the companies involved in the development and manufacture of influenza vaccines in China, Hong Kong, and Macau. GSK will pay Shenzhen Neptunus $39 million, after which GSK will be the sole owner of the joint venture

Continue Reading

Amgen has been boosted by the news that regulators in the European Union have given the green light to Xgeva for cancer-related fractures.

Amgen has been boosted by the news that regulators in the European Union have given the green light to Xgeva for cancer-related fractures. Specifically, the European Commission has granted marketing authorisation for Xgeva (denosumab) for the prevention of skeletal-related events in adults with bone metastases from solid tumours. The Commission has also granted the drug

Continue Reading

Quintiles plans more Prime Sites in UK

Quintiles is considering setting up at least two more Prime Sites in the UK to make the most of what it regards as a still fertile environment for clinical trials. The US-based biopharmaceutical services company established the first of its international network of Prime Sites at Queen Mary, University of London in 2007. The company recently gave a further vote of confidence to the UK as a key location for clinical research by investing in a clinical research facility – part of the new William Harvey Heart Centre – at the same site.

Continue Reading